A prospective phase II study, the ASPIRATION trial, investigated the efficacy of first-line erlotinib therapy in patients with NSCLC with activating EGFR mutations and post-progression erlotinib therapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.